Healthcare / Elderly CareUS
← Sticker Wall
JOURNEY · DETAIL
Moderna: A Decade-Long Gamble on mRNA Without Products, and the Post-COVID Transformation Crisis
Founded: Noubar Afeyan, Derrick Rossi, Stéphane Bancel, and other industry team members · Moderna, Inc.
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionUS
ScaleGiant
ChannelOther
Origin
Around 2010, Harvard stem cell biologist Derrick Rossi discovered that modified mRNA could express target proteins within cells. Noubar Afeyan of the venture firm Flagship Pioneering realized this could be the foundation for a company that treats mRNA as a software platform. Moderna was founded in 2010 with the vision that if mRNA sequences are treated as code and lipid nanoparticles as an operating system, drug development could be compressed from decades to days. To achieve this, the company spent billions of dollars from financing and pharmaceutical partnerships over ten years without launching a single product, solely to build the platform.
Milestones
2010
Founding and Stealth R&D Failure
After its founding in 2010, Moderna remained in stealth mode for a long time. Early direct mRNA injections caused severe toxic side effects, and animal experiments repeatedly failed. The company internally pivoted toward safer, localized delivery and small-dose treatments for rare diseases to bypass immune toxicity. Many early executives left, and the industry widely doubted that mRNA drugs were viable. This phase lasted from 2010 to 2015.
2018
IPO Financing Turning Point
In December 2018, Moderna went public on NASDAQ, raising approximately $604 million—the largest biotech IPO in history at the time—with a valuation of about $7.5 billion. However, eight years after its founding, the company still had no approved products and relied entirely on financing and partnership funds, with losses widening annually.
2020
COVID-19 Vaccine Race PMF
After the COVID-19 genetic sequence was released in January 2020, Moderna designed its vaccine sequence in just two days. It entered clinical trials in March and received U.S. Emergency Use Authorization in December. The 43-day turnaround from sequence to first human dosing shocked the industry, marking the first time the platform's decade of accumulation translated into a real product.
2021
Peak Performance Growth
In 2021, Moderna reached $18.5 billion in revenue and approximately $12.2 billion in net profit, jumping from a perennial loss-maker to one of the world's most profitable biotech companies. Its stock price peaked at around $497, with a market cap briefly exceeding $190 billion. The company began aggressively expanding its cancer and flu vaccine pipelines. This phase lasted from 2021 to 2022.
2023
Pandemic Ebb Failure
As vaccine demand plummeted, Moderna's revenue fell from $19.3 billion in 2022 to $6.8 billion in 2023, and further to around $3.2 billion in 2024. Starting in 2023, the company shifted to significant losses, and its stock price dropped by approximately 94% from its peak over four years. The company was forced to lay off staff, cut pipelines, and slash R&D spending by billions. This phase lasted from 2023 to 2024.
2026
Cancer Vaccine Reversal Turning Point
In August 2026, the personalized neoantigen mRNA cancer vaccine for melanoma, developed with Merck, succeeded in Phase 3 trials. This was viewed as the definitive proof of mRNA technology beyond COVID-19. The stock price surged 177% on the day of the announcement, as the market revalued the company for the post-pandemic era.
Turning Points
- In 2020, the 43-day sprint from sequence to human trials for the COVID-19 vaccine turned a decade-long platform gamble into a reality overnight.
- The record-breaking 2018 IPO secured the funding needed to survive the decade of cash-burning, without which it would not have lasted until its product launch.
- After the pandemic windfall faded, revenue shrank by over 80%, forcing a shift from expansion to survival mode.
- The 2026 success of the melanoma cancer vaccine shifted the company's narrative from a 'vaccine stock' to a 'cancer platform stock'.
Failures & Pitfalls
- For the first seven years, no products were launched; all drug candidates stalled in preclinical or early-stage trials.
- Early mRNA injections triggered severe immune toxicity, forcing a pivot from intravenous delivery to more conservative routes.
- Over-reliance on a single blockbuster vaccine during the COVID-19 boom led to a revenue collapse to $6.8 billion in 2023 once demand waned.
- The stock price fell by approximately 94% from its 2021 peak to around 2025, as investors voted with their feet, rejecting the valuation of its pipeline.
关键成功要素
- Treating mRNA as a programmable platform rather than a single drug development project, allowing sequence design and delivery systems to be reused across all indications.
- The courage to continue financing while having no products, using capital patience to hedge against technical uncertainty.
- Government orders and emergency authorization mechanisms allowed the COVID-19 vaccine to be commercialized at record speed.
- Timely reinvestment of profits into second-curve projects like cancer vaccines to ensure the company had a pipeline after the primary vaccine became obsolete.
Lessons
- The moat of a deep-tech company often takes a decade of losses and ridicule before it becomes visible.
- The peak revenue from a single blockbuster will vanish when the trend fades; a second growth curve must be planted in advance.
- For a platform-based biotech company, financing capability is as important as R&D capability; running out of cash is more fatal than technical failure.
- Treating a temporary market frenzy as a permanent balance sheet is dangerous; Moderna's layoffs and pipeline cuts stemmed from misjudgments at the peak.
- Technical vindication often requires a second clinical success; one hit is not enough to support long-term valuation.
Core Data
- 2021 Revenue：$18.5 billion (based on public data, not independently verified)
- 2021 Net Profit：$12.2 billion (based on public data, not independently verified)
- 2022 Revenue：$19.3 billion (based on public data, not independently verified)
- 2023 Revenue：$6.8 billion (based on public data, not independently verified)
- 2024 Fiscal Year Revenue：Approximately $3.2 billion (based on public data, not independently verified)
- 2018 IPO Proceeds：$604 million (based on public data, not independently verified)
- Maximum Stock Price Decline：Approximately 94% from a peak of about $497 (based on public data, not independently verified)
- 2026 Single-Day Gain：177% (based on public data, not independently verified)
- Historical Stock Peak：Approximately $497 (based on public data, not independently verified)
Competitors / Peers
In the mRNA space, the Pfizer and BioNTech partnership (Comirnaty) shared the COVID-19 windfall and faced a similar decline. In the cancer vaccine field, players such as CureVac, BioNTech, Stemirna, and Abogen are catching up with personalized neoantigen and universal vaccines. In a broader sense, giants with mature immunotherapies like Merck's Keytruda are both key partners and ultimate rivals in the oncology market.